Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor versus physician's choice for relapsed/refractory AML in older patients ineligible for intensive therapy
NL-OMON41919Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selinexor in acute myeloid leukemia (AML) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall survival. Started Mar 2015; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON41919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41919.